SpringerLink
Log in

Suppression of Th1 cytokine production by a peptide derived from C4b

  • Original Research Paper
  • Published:
Inflammation Research Aims and scope Submit manuscript

Abstract

Objectives

The complement system has been proposed to play a significant role in the regulation of T-cell responses. However, the precise mechanism underlying C4-induced immune tolerance remains to be clarified. We recently reported that monomeric C4b inhibits CXCL10 production from blood cells. The purpose of this study was to verify the active site of monomeric C4b.

Materials and methods

We investigated the in vitro effects of a C4b-derived peptide (VPAGSARPVAFSVVPTAAA), named HP2 (highly homologous peptide 2), on the IFN-β-induced production of CXCL10 in human blood and the in vivo effects of the administration of HP2 on Th1/2 cytokine production in the spleen in mice. We also tested whether the administration of HP2 influences symptoms of experimentally induced ulcerative colitis in mice.

Results

HP2 inhibited CXCL10 production in human blood, and the administration of HP2 significantly suppressed the production of Th1 cytokines, such as IL-2, IFN-γ, and TNF-α, in spleen cells isolated from mice. The administration of HP2 in the mice significantly improved the symptoms of colitis, with down-regulation of colitogenic CD4+CD45RBhigh T cells and up-regulation of CD4+LAP/TGF-β1+ T cells.

Conclusion

The amino acid sequence described above is suggested to be the active site in C4b for the inhibition of Th1 cytokine production. These results should contribute to the development of new drugs suppressing autoimmune responses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Thailand)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Kemper C, Atkinson JP. T-cell regulation: with complements from innate immunity. Nat Rev Immunol. 2007;7:9–18.

    Article  PubMed  CAS  Google Scholar 

  2. Sturfelt G, Truedsson L. Complement and its breakdown products in SLE. Rheumatology (Oxford). 2005;44:1227–32.

    Article  CAS  Google Scholar 

  3. Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol. 2004;22:431–56.

    Article  PubMed  CAS  Google Scholar 

  4. Paul E, Pozdnyakova OO, Mitchell E, Carroll MC. Anti-DNA auto reactivity in C4-deficient mice. Eur J Immunol. 2002;32:2672–9.

    Article  PubMed  CAS  Google Scholar 

  5. Walport MJ. Complement. First of two parts. N Engl J Med. 2001;344:1058–66.

    Article  PubMed  CAS  Google Scholar 

  6. Carroll MC. A protective role for innate immunity in systemic lupus erythematosus. Nat Rev Immunol. 2004;4:825–31.

    Article  PubMed  CAS  Google Scholar 

  7. Chen Z, Koralov SB, Kelsoe G. Complement C4 inhibits systemic autoimmunity through a mechanism independent of complement receptors CR1 and CR2. J Exp Med. 2000;192:1339–52.

    Article  PubMed  CAS  Google Scholar 

  8. Santer DM, Hall BE, George TC, Tangsombatvisit S, Liu CL, Arkwright PD, et al. C1q deficiency leads to the defective suppression of IFN-α in response to nucleoprotein containing immune complexes. J Immunol. 2010;185:4738–49.

    Article  PubMed  CAS  Google Scholar 

  9. Takeda Y, Kaneda K, Jimma F, Shiobara N, Hidaka M, Saniabadi AR, et al. Inhibition of CXCL10 release by monomeric C3bi and C4b. Clin Exp Immunol. 2012;167:149–57.

    Article  PubMed  CAS  Google Scholar 

  10. Ito R, Shin-Ya M, Kishida T, Urano A, Takada R, Sakagami J, et al. Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin Exp Immunol. 2006;146:330–8.

    Article  PubMed  CAS  Google Scholar 

  11. Law SK, Dodds AW. The internal thioester and the covalent binding properties of the complement proteins C3 and C4. Protein Sci. 1997;6:263–74.

    Article  PubMed  CAS  Google Scholar 

  12. Onoe K, Yanagawa Y, Minami K, Iijima N, Iwabuchi K. Th1 or Th2 balance regulated by interaction between dendritic cells and NKT cells. Immunol Res. 2007;38:319–32.

    Article  PubMed  CAS  Google Scholar 

  13. Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol. 1993;5:1461–71.

    Article  PubMed  CAS  Google Scholar 

  14. Powrie F, Carlino J, Leach MW, Mauze S, Coffman RL. A critical role for transforming growth factor-β but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RBlow CD4+ T cells. J Exp Med. 1996;183:2669–74.

    Article  PubMed  CAS  Google Scholar 

  15. Oida T, Zhang X, Goto M, Hachimura S, Totsuka M, Kaminogawa S, et al. CD4+CD25− T cells that express latency-associated peptide on the surface suppress CD4+CD45RBhigh-induced colitis by a TGF-β-dependent mechanism. J Immunol. 2003;170:2516–22.

    PubMed  CAS  Google Scholar 

  16. Kamanaka M, Huber S, Zenewicz LA, Gagliani N, Rathinam C, O’Connor W Jr, et al. Memory/effector [CD45RB(lo)] CD4 T cells are controlled directly by IL-10 and cause IL-22-dependent intestinal pathology. J Exp Med. 2011;208:1027–40.

    Article  PubMed  CAS  Google Scholar 

  17. Kurowska-Stolarska M, Kewin P, Murphy G, Russo RC, Stolarski B, Garcia CC, et al. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol. 2008;181:4780–90.

    PubMed  CAS  Google Scholar 

  18. Pastorelli L, De Salvo C, Cominelli MA, Vecchi M, Pizarro TT. Novel cytokine signaling pathways in inflammatory bowel disease: insight into the dichotomous functions of IL-33 during chronic intestinal inflammation. Therap Adv Gastroenterol. 2011;4:311–23.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Mr. Hiromu Shibusawa for his valuable technical support.

Author information

Authors and Affiliations

  1. Department of Environmental and Preventive Medicine, Hyogo College of Medicine, Mukogawa-cho 1-1, Nishinomiya, Hyogo, 663-8501, Japan

    Yuji Takeda & Ichiro Wakabayashi

  2. JIMRO Institute, Immunoresearch Division, 351-1 Nishiyokote-cho, Takasaki, Gunma, 370-0021, Japan

    Kenta Kaneda, Fumie Jimma, Noriyuki Shiobara & Abbi R. Saniabadi

Authors
  1. Yuji Takeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenta Kaneda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fumie Jimma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Noriyuki Shiobara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Abbi R. Saniabadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ichiro Wakabayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ichiro Wakabayashi.

Additional information

Responsible Editor: Andras Falus.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Takeda, Y., Kaneda, K., Jimma, F. et al. Suppression of Th1 cytokine production by a peptide derived from C4b. Inflamm. Res. 62, 951–959 (2013). https://doi.org/10.1007/s00011-013-0650-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00011-013-0650-z

Keywords

Search

Navigation